Brain Initiative: Research to Develop and Validate Advanced Human Cell-Based Assays To Model Brain Structure and Function (R01 Clinical Trial Not Allowed) | RFA MH 20 140

Opportunity Information: Apply for RFA MH 20 140

The National Institutes of Health (NIH) released this grant opportunity under the BRAIN Initiative to push the field toward more realistic, next-generation human cell-based laboratory models of the brain and nervous system. The program is focused on creating and validating advanced assays made from human cells that can reproduce key features of brain structure and function with much higher biological fidelity than many of today s simplified culture systems. The overall goal is to give researchers better experimental platforms for studying how complex neural circuits form, operate, change with age, and break down in disease, without relying on approaches that are limited in their ability to mimic real human nervous system architecture and physiology.

A central emphasis of the announcement is on building assays that capture complexity. In practice, that means systems that go beyond basic two-dimensional cell cultures and instead more closely resemble the three-dimensional organization, cell type diversity, connectivity, and functional dynamics seen in actual nervous tissue. The FOA points toward models that can reflect complex nervous system architectures and physiological behavior, which may include features such as layered structures, multiple interacting neural and non-neural cell types, synaptic network activity, circuit level signaling, and measurable functional outputs that correspond to meaningful aspects of neural function. NIH is looking not just for new tools, but for assays that are robust enough to serve as credible experimental stand ins for studying development, function, and aging in both healthy and disease contexts.

Another important element is the expectation of validation. Projects are not only supposed to develop these human cell-derived platforms, but also to demonstrate that they truly model brain relevant structure and function in a reliable, interpretable way. Validation in this context generally means showing that the assay can reproduce known biological phenomena, generate consistent results, and provide measurable readouts that can be compared against established benchmarks. The announcement frames these awards as enabling infrastructure for future neuroscience research: the deliverable is a well characterized assay system that other studies can then use to investigate mechanisms of development, degeneration, or dysfunction. In other words, the NIH is investing in the foundation, not just one-off experiments.

The FOA also explicitly encourages technologies that do not rely on human fetal tissue, referencing NIH guidance described in NOT-19-042. That reflects a programmatic preference for alternatives that can achieve high fidelity modeling while avoiding reliance on fetal tissue based methods. Applicants are expected to design their approaches accordingly, using human cell sources and methodologies that fit within that policy direction while still meeting the scientific objective of faithfully reproducing complex neural biology.

This is an R01 funding mechanism, meaning it is intended for substantial, multi-year research projects with a clear plan, strong preliminary rationale, and well defined milestones. The opportunity is labeled Clinical Trial Not Allowed, which means the proposed work must be preclinical and methodology focused rather than involving prospective assignment of human participants to interventions to evaluate health related outcomes. The funding opportunity number is RFA-MH-20-140, and it falls under the NIH discretionary grant category, with activity areas spanning education, health, and related social services classifications as reflected in the listed CFDA numbers (93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866, 93.867). The original closing date shown for this specific announcement was 2019-11-01, and the listed award ceiling is $500,000, indicating an upper limit on the amount expected per award under the terms presented in the source information. The record also notes an expected awards field but does not provide a number in the excerpted data.

Eligibility is broad and includes a wide range of organizations that can carry out biomedical research. Standard eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (other than higher education institutions); for-profit organizations other than small businesses; small businesses; and other entities. The announcement also calls out additional eligible applicant categories, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). This broad eligibility aligns with the BRAIN Initiative s goal of accelerating tool and platform development across academia, industry, nonprofit research environments, and diverse institutional settings.

Taken together, the opportunity is essentially a targeted investment in better human cell-based experimental systems for neuroscience. NIH is signaling that the field needs more predictive and biologically realistic models that can represent the complexity of neural tissue, generate meaningful functional readouts, and be validated well enough to become widely usable platforms. The expected impact is not limited to one disease or one narrow application; instead, these assays are meant to unlock future research on nervous system development, everyday function, aging, and a range of disease states by providing models that behave more like real human brain tissue than existing alternatives.

• The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "Brain Initiative: Research to Develop and Validate Advanced Human Cell-Based Assays To Model Brain Structure and Function (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866, 93.867.
• This funding opportunity was created on 2019-05-31.
• Applicants must submit their applications by 2019-11-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA MH 20 140

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: